Erythrocyte Na+,K+-ATPase activity does not predict therapeutic response to calcium antagonists in essential hypertension
Küçük Resim Yok
Tarih
1994
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
We investigated whether pre- and posttreatment analysis of erythrocyte membrane Na+,K+-ATPase (EC 3.6.1.37) activity would be a useful marker for screening hypertensive patients to determine who might benefit from treatment with calcium antagonists. Erythrocyte Na+,K+-ATPase activity and sodium and potassium (ENa, EK) contents were determined in controls and in patients with untreated essential hypertension before and after 4 weeks of treatment with nitrendipine. Na+,K+-ATPase activity was significantly (P <0.0001) less in untreated hypertensive patients (n = 15; 104.60 ± 29.37 nmol of phosphate produced per milligram of protein per hour) than in controls (n = 15, 171.87 ± 34.42). After 4 weeks of nitrendipine treatment Na+,K+-ATPase activity was greater than in the pretreatment group: 158.13 ± 26.80 (P <0.001). Pretreatment ENa contents (22.34 ± 4.77 mmol/L) were significantly (P <0.0001) higher than in the normotensive group (13.14 ± 3.32 mmol/L), but there was no significant difference between the controls and the posttreatment group (14.84 ± 3.49 mmol/L). The control and pretreatment groups showed negative correlations between enzyme activity and systolic/diastolic blood pressure (P <0.0001). The control and the posttreatment groups showed an inverse correlation between enzyme activity and ENa contents: r = -0.608 (P <0.05) and r = -0.724 (P <0.001), respectively. Although Na+,K+-ATPase is restored in hypertensive patients receiving nitrendipine treatment, relative changes in enzyme activity in relation to relative reduction in blood pressure response to treatment were not correlated.
Açıklama
Anahtar Kelimeler
Kaynak
Clinical Chemistry
WoS Q Değeri
Scopus Q Değeri
N/A
Cilt
40
Sayı
8
